Various aspects of this disclosure relate to a composition, comprising a liquid phase that consists of chemical species that comprise tetrahydrocannabinol, one or more flavyliums, and a solvent, wherein each chemical species of the liquid phase has a concentration in the liquid phase; the tetrahydrocannabinol is dissolved in the liquid phase at a concentration of at least 0.1 percent and no greater than 8 percent by mass; each flavylium of the one or more flavyliums is a substituted 2-phenylchromenylium that consists of carbon, hydrogen, and oxygen atoms; the solvent is miscible with water; and the liquid phase comprises the solvent at a greater concentration by mass than any other chemical species of the liquid phase.

A method for producing cannabinoid-containing crystals includes providing a CBGA-containing plant material that includes at least 2% CBGA by dry weight. The CBGA-containing plant material is exposed to a fluid in a supercritical state to extract components of the CBGA-containing plant material. A fraction of the extracted components is coalesced. The coalesced fraction of the extracted components includes cannabinoid-containing crystals containing at least one of CBGA and a cannabinoid derivative of CBGA from the carbon dioxide.

The invention relates to the preparation of a hydrophilic edible emulsified drug delivery system (SENE) which presents poorly soluble medicaments in a solubilized dispersion. The SENE further includes a combination of surfactants having an HLB of between 8-15 and a solvent/stabilizer. The SENE has practically no taste and yields highly translucent and fully water-compatible nano-emulsions.

Compositions and methods for treating or reducing symptoms of COVID-19 are provided herein. An exemplary method includes administering to the subject an effective amount of cannabidiol to reduce acute respiratory distress syndrome caused by COVID-19.

The present disclosure is directed to a method for treating an autoimmune disease, the method comprising administering to a subject in need thereof a cannabinoid compound comprising delta-8-tetrahydrocannabinol.

The present invention is directed to a pharmaceutical composition including at least one cannabinoid or combination thereof, and methods of using same, such as for preventing, reducing or inhibiting the growth of a nasal polyp in a subject in need thereof.

The present disclosure provides for compositions combining Cannabinoid Fractions and Mushroom Extract Fractions for recreational and medicinal uses. The disclosed compositions are useful for treating symptoms of anxiety, stress, pain, and promoting sleep. The pharmaceutical compositions comprise particular cannabinoid ratios and terpene profiles.

Various aspects of this disclosure relate to a composition, comprising a liquid phase that consists of chemical species that comprise tetrahydrocannabinol, one or more flavyliums, and a solvent, wherein each chemical species of the liquid phase has a concentration in the liquid phase; the tetrahydrocannabinol is dissolved in the liquid phase at a concentration of at least 0.1 percent and no greater than 8 percent by mass; each flavylium of the one or more flavyliums is a substituted 2-phenylchromenylium that consists of carbon, hydrogen, and oxygen atoms; the solvent is miscible with water; and the liquid phase comprises the solvent at a greater concentration by mass than any other chemical species of the liquid phase.

Certain embodiments of the present application relate to a dry composition for preparing a nasal rinse. The dry composition generally includes cannabidiol and a mixture comprising sodium chloride and sodium bicarbonate. In certain forms, the dry composition has less than one percent by weight water. In certain embodiments, the cannabidiol is a water-soluble cannabidiol.

Oral cannabinoid pharmaceutical compositions and methods of treating inflammatory gastrointestinal disorders using the oral cannabinoid pharmaceutical compositions are described.